🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Suzanne M. Cadarette

University of North Carolina at Chapel Hill

ORCID: 0000-0002-8584-9649

Also affiliated with 3M (United States), Toronto Public Health, University of Toronto, Muscular Dystrophy Canada, Public Health Ontario, Institute for Clinical Evaluative Sciences

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Disease risk score as a confounder summary method: systematic review and recommendations: DRS AS A CONFOUNDER SUMMARY METHOD”.

Disease risk score as a confounder summary method: systematic review and recommendations: DRS AS A CONFOUNDER SUMMARY METHOD

UNC Libraries(2020)10.17615/6z3g-4q88
N/A
0DataRank · unranked
0 citations

Mina Tadrous, Suzanne M. Cadarette, Joshua J. Gagne, Til Stürmer‎

Placebo Adherence, Clinical Outcomes, and Mortality in the Womenʼs Health Initiative Randomized Hormone Therapy Trials

UNC Libraries(2020)10.17615/0p9x-5054
N/A
0DataRank · unranked
0 citations

Monika M. Safford, Jeffrey R. Curtis, M. Alan Brookhart, Suzanne E. Judd, Suzanne M. Cadarette +5 more

Confounder summary scores when comparing the effects of multiple drug exposures

UNC Libraries(2020)10.17615/8qk3-gs19
N/A
0DataRank · unranked
0 citations

Til Stà ⁄ rmer, Jeffrey N. Katz, Suzanne M. Cadarette, Daniel H. Solomon, Joshua J. Gagne

Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications

Bone Reports(2023)10.1016/j.bonr.2023.101730
N/A
0DataRank · unranked
6 citations

Suzanne M. Cadarette, Andrea M. Burden, Kaleen N. Hayes

On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal

JBMR Plus(2024)10.1093/jbmrpl/ziae027
N/A
0DataRank · unranked
6 citations

Angela M. Cheung, Sandra Kim, Tara Gomes, Suzanne M. Cadarette, Anna Rzepka

On-time denosumab dosing recovered rapidly during the COVID-19 pandemic, yet remains suboptimal

UNC Libraries(2024)10.17615/dd7z-2f08
N/A
0DataRank · unranked
1 citations

Suzanne M. Cadarette, Angela M. Cheung, Sandra Kim, Tara Gomes, Anna Rzepka

Real-world differences in denosumab persistence, reinitiation, and switching among cohorts of older adults in Canada and the United States

JBMR Plus(2025)10.1093/jbmrpl/ziaf061
N/A
0DataRank · unranked
8 citations

Selvam R Sendhil, Sulbh Aggarwal, Andrew R. Zullo, Sarah D. Berry, Arman Oganisian +3 more

Design aspects for prognostic factor studies

BMJ Open(2025)10.1136/bmjopen-2024-095065
N/A
0DataRank · unranked
4 citations

Inga Steinbrenner, Ulla T. Schultheiß, Neus Valveny, Paola Rebora, Susan Halabi +6 more

Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries

Osteoporosis International(2025)10.1007/s00198-025-07668-x
N/A
0DataRank · unranked
0 citations

Suzanne M. Cadarette, Sulbh Aggarwal, Arman Oganisian, Andrew R. Zullo, Sarah D. Berry +3 more

A scoping review of real-world evidence generation methods to estimate the safety of type 2 diabetes medications on fracture risk

Osteoporosis International(2025)10.1007/s00198-025-07745-1
N/A
0DataRank · unranked
0 citations

Freddy F. Shogry, Stephen Park, Nicholas Bakewell, Kaleen N. Hayes, Andrea M. Burden +3 more